The degree of consumption of neutralizing antibodies against LPS endotoxin core antigen, expressed by low levels of EndoCab IgM (median, IQR MU/mL), was significantly higher in COVID-19 patients compared to HD at T0 [60.59 (26.45-103.3) vs 163 (128-211.5), respectively, p<0.0001]. The gene discussed is CD40LG; the disease is COVID-19.